Side-by-side comparison of AI visibility scores, market position, and capabilities
Telehealth platform making ketamine-assisted therapy accessible for treatment-resistant depression, anxiety, and PTSD.
Nue Life is a Miami-based mental health company that provides at-home ketamine-assisted therapy for treatment-resistant depression, anxiety, PTSD, and OCD through a telehealth model. The company pairs oral ketamine with therapeutic coaching and integration support to treat patients who have not responded to traditional antidepressants. Nue Life's model addresses barriers to ketamine therapy — geographic access to ketamine clinics and prohibitive out-of-pocket costs — by delivering treatment at home with telehealth physician oversight and licensed therapist integration support. The platform has treated thousands of patients with documented outcomes data and published case studies. Nue Life operates in the rapidly growing psychedelic-assisted therapy market, which has seen significant clinical validation for ketamine and clinical trial progress for MDMA and psilocybin. Founded in 2020, the company has raised funding to expand access to ketamine therapy while the regulatory environment for psychedelic medicine continues to evolve.
Adept AI raised $415M to pioneer computer-use AI agents; its core research and agent team moved to Amazon in 2024 in a landmark talent acquisition while the company continues developing ACT-1 for enterprise automation.
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and executing multi-step workflows in any application. Its ACT-1 model demonstrated the ability to control web browsers and desktop applications through natural language instructions, pioneering the computer-use agent paradigm that Anthropic later commercialized with Claude's computer use feature.
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.